Strategy of Transfusion in Trauma Patients - STATA Trial (STATA)

November 1, 2016 updated by: University of Sao Paulo General Hospital

Clinical Trial: Evaluation of 2 Different Protocols of Blood Derivates Transfusion in Acute Trauma Patients in a Brazilian Tertiary Hospital

The purpose of this study is to compare two already validated methods for massive transfusion in trauma patients admitted to the emergency room of a large reference hospital.

Study Overview

Status

Completed

Conditions

Detailed Description

In this randomized trial trauma patients in need of massive transfusion will be assigned to one of the following transfusion strategies:

  1. - Fresh Frozen Plasma, Platelets Concentrate and Packed red blood cells in 1:1:1 ratio.
  2. - These patients will receive Red blood cells based on Haemoglobin measurements and will receive either Beriplex® P/N (CSL Behring GmbH, Marburg, Germany) or Haemocomplettan® P (CSL Behring, Marburg, Germany), or Platelets based on thromboelastometry.

To be included patients must meet the following inclusion criteria:

  1. - Trauma victims
  2. - Adults between 18 - 80 years old
  3. - Injury Severity Score (ISS) between 15 and 45
  4. - Assessment of Blood Consumption (ABC) Score ≥ 3 points
  5. - Shock Index ≥ 1,2
  6. - Acute hemorrhage of more than 50% estimated blood volume in 3 hours or more than 1,5 ml/kg/min of blood during 20 minutes.

Exclusion Criteria:

  1. - Early cardiac arrest
  2. - Pregnancy
  3. - Injury Severity Score (ISS) > 45
  4. - Patient transferred from another hospital
  5. - Drug abuse history
  6. - Known coagulation impairment
  7. - Known use of anticoagulants, or platelet antiaggregants.

The group of health-care providers recruiting the patients based on eligibility criteria, is different than the group that evaluates the clinical outcomes of the included patients, in such a way that no researcher is tasked with post-randomisation care of the subjects. This is done to prevent observational bias.

Two informed consent forms are signed for each patient. The first one is signed by an independent physician. Another consent form is signed by the patient's family or the own patient within 24 hours of hospital admission.

The randomisation is performed by sealed envelopes assigned to the eligible patients anytime they reach the protocol criteria. The envelopes were created using a computer generated randomisation table specifically designed to this study.

An interim analysis was performed in October 2015 and it showed that there was no increased mortality or morbidity within the intervention group.

Study Type

Interventional

Enrollment (Actual)

156

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • SP
      • Sao Paulo, SP, Brazil, 05403-000
        • Hospital das Clinicas FMUSP

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Trauma victims
  • Adults between 18 - 80 years old
  • Injury Severity Score (ISS) between 15 and 45
  • Assessment of Blood Consumption (ABC) Score ≥ 3 points
  • Shock Index ≥ 1,2

Exclusion Criteria:

  • Early cardiac arrest
  • Pregnancy
  • ISS > 45
  • Patient transferred from another hospital
  • Drug abuse history
  • Known coagulation impairment
  • Known use of anticoagulants, or platelet anti-aggregants. -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Blood Products only.
This arm will receive 1:1:1 Red blood cells : Fresh Frozen Plasma : Platelets upon a major trauma triggers. 1:1:1 Ratio for packs of blood products. The patient will be re-evaluated every hour again for the major bleeding triggers and another 1:1:1 intervention may or may not occur.
Based solely on massive transfusion triggers Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive blood products by prescription of the patient's anesthesiologist. The patient will be constantly observed and bleeding triggers will be reassessed hourly.
Other Names:
  • Red blood cells
  • Platelets
  • Fresh frozen plasma
Experimental: Point of care guided
This arm will receive Red blood cells, Human Fibrinogen and Prothrombinic complex concentrates (PCC) based on thromboelastometry. The dosis of each drug will be determined by the analyses of the thromboelastometry curves.
Based on massive transfusion triggers and thromboelastometry Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive the drugs guided by the results of the thromboelastometry. The dosis of each drug will be based on the analysis of the thromboelastometry curves (established algorithm).
Other Names:
  • Red blood cells
  • Beriplex® P/N (CSL Behring GmbH, Marburg, Germany)
  • Haemocomplettan® P (CSL Behring, Marburg, Germany)
  • Prothrombin Complex Concentrates (PCC)
  • Human Fibrinogen

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SOFA Score - 5 days
Time Frame: 5 days
Evaluation of the SOFA score along the first 5 days after the patient admission.
5 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Roseny R Rodrigues, M.D., Hospital das Clínicas HC-FMUSP

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2014

Primary Completion (Actual)

July 1, 2016

Study Completion (Actual)

July 1, 2016

Study Registration Dates

First Submitted

August 28, 2014

First Submitted That Met QC Criteria

April 9, 2015

First Posted (Estimate)

April 15, 2015

Study Record Updates

Last Update Posted (Estimate)

November 2, 2016

Last Update Submitted That Met QC Criteria

November 1, 2016

Last Verified

November 1, 2015

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

Individual patient data collected can be shared if needed.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Wounds and Injuries

Clinical Trials on Blood Products only

3
Subscribe